TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32492069
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg (injection frequency ≥5)
Study: 32492942
Drug: Cilostazol SR
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol SR capsule (200-mg)
Study: 32492942
Drug: DAPT alone
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT alone (clopidogrel and aspirin)
Study: 32493206
Drug: Erenumab 140-mg
Normalized name: erenumab-aooe 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 140-mg monthly by two subcutaneous 1-mL injections, given every 4 weeks for 12 weeks
Study: 32493448
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin A supplementation (3000 UI/kg/die for 28 days)
Study: 32496203
Drug: Sham control
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham control group (daily sham text messages)
Study: 32496541
Drug: Time from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time from diagnosis to treatment (TDT) of 0 to 5 days
Study: 32496541
Drug: Time from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time from diagnosis to treatment (TDT) of 6 to 10 days
Study: 32496541
Drug: Time from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time from diagnosis to treatment (TDT) of 11 to 15 days
Study: 32496541
Drug: Time from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time from diagnosis to treatment (TDT) of >15 days
Study: 32496557
Drug: Near-infrared photoimmunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Near-infrared photoimmunotherapy (NIR-PIT) using RM1929/ASP1929 (anti-EGFR antibody plus IRDye700DX)
Study: 32497409
Drug: Weekly prophylaxis
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly prophylaxis (WP)
Study: 32497409
Drug: Modified prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified prophylaxis or episodic treatment
Study: 32497440
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection (RCI, Acthar® Gel) as adjunctive therapy along with DMARDs and glucocorticoids
Study: 32497499
Drug: Single-cell RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-cell RNA and paired T cell receptor (TCR) sequencing
Study: 32499275
Drug: Panenteric capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panenteric capsule endoscopy (CE)
Study: 32499730
Drug: Theta-burst stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theta-burst stimulation (TBS) administered for 6 weeks (5 days a week for the first 3 weeks, then 2 days a week for the next 3 weeks) in the dorsolateral prefrontal cortex.
Study: 32500620
Drug: Intra-articular autologous
Normalized name: autologous cultured chondrocytes 1.2e+007 INTRA-ARTICULAR IMPLANT [CARTICEL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular autologous bone marrow aspirate (BMA) injections
Study: 32501454
Drug: High-dose anakinra
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: High-dose anakinra (5 mg/kg twice a day intravenously)
Study: 32501454
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (200 mg hydroxychloroquine twice a day and 400 mg lopinavir with 100 mg ritonavir twice a day)
Study: 32501528
Drug: Filanesib in
Normalized name: Filanesib
DrugBank: Filanesib (DB06040)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filanesib in combination with pomalidomide and dexamethasone
Study: 32502272
Drug: Adjuvanted recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted recombinant zoster vaccine (RZV) - 2 initial doses
Study: 32502272
Drug: Adjuvanted recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted recombinant zoster vaccine (RZV) - 1 additional dose
Study: 32502272
Drug: Adjuvanted recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted recombinant zoster vaccine (RZV) - 2 additional doses
Study: 32502277
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency (25(OH)D <50 nmol/l)
Study: 32502277
Drug: Severe vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe vitamin D deficiency (25(OH)D <25 nmol/l)
Study: 32502506
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (Carboplatin/etoposide and cyclophosphamide/etoposide regimens, 4 cycles every 3 weeks) followed by radiation therapy (RT)
Study: 32502506
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (18 Gy craniospinal RT for metastatic tumors, whole brain RT for basal ganglia tumors, or whole ventricular RT followed by 12.6 Gy boost RT)
Study: 32503441
Drug: Baseline assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline assessment including self-administered PA and ST questionnaires and standardized measurement of blood pressure, waist circumference, and blood parameters; no treatment or intervention after 5 weeks
Study: 32503469
Drug: Nivolumab and
Normalized name: nivolumab and relatlimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab and entinostat (2 mg/m2)
Study: 32503811
Drug: Medical compression
Normalized name: Truform Medical Compression Stockings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical compression therapy (classes I and II)
Study: 32503866
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care - information leaflets and access to supervised exercise programmes, physical therapy, and healthy lifestyle programmes.
Study: 32503947
Drug: murlentamab treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: murlentamab treatment
Study: 32503950
Drug: Nivolumab and
Normalized name: nivolumab and relatlimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab and Ipilimumab combination therapy
Study: 32506317
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg twice daily (BID), with adjustments to 10 mg BID permitted post-month 1.
Study: 32506317
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg BID, with adjustments to 10 mg BID permitted post-month 1.
Study: 32506428
Drug: Biological senescence
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological senescence group
Study: 32506695
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with golimumab
Study: 32507584
Drug: Increasing daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing daily volume of YCF consumed at age 24 months
Study: 32508029
Drug: Apatinib 500
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500 mg + gefitinib 250 mg (Cohort A)
Study: 32508029
Drug: Apatinib 250
Normalized name: lapatinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 250 mg + gefitinib 250 mg (Cohort B)
Study: 32508541
Drug: Saline (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (single bolus dose)
Study: 32509978
Drug: Daily cow's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cow's milk intake >2 cups
Study: 32510046
Drug: High load
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High load treatment
Study: 32510046
Drug: Low load
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low load treatment
Study: 32511251
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (1,000 mg) infusion on the first day of treatment
Study: 32511251
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (1,000 mg) infusion
Study: 32511534
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of Nitric Oxide (NO)
Study: 32511695
Drug: Oral capsulized
Normalized name: Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsulized fecal microbiota transplantation (FMT) for 2 days
Study: 32511695
Drug: Post-FMT antibiotics
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-FMT antibiotics
Study: 32511695
Drug: CPE carriers
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPE carriers who failed treatment
Study: 32512291
Drug: Valsartan (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (titrated to blood pressure up to a maximum of 160 mg bid)
Study: 32513113
Drug: VPIA analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPIA analgesic infusion pump
Study: 32513801
Drug: Meropenem 40
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem 40 mg/kg/dose every 8 hours as a 4-hour infusion
Study: 32513801
Drug: Meropenem 110
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem 110 mg/kg/day as a continuous infusion
Study: 32514450
Drug: Sodium-glucose cotransporter
Normalized name: glucose / sodium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-glucose cotransporter 2 (SGLT2) inhibitors for 12 weeks
Study: 32514886
Drug: 5-ALA (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ALA (200 mg/kg intraperitoneal)
Study: 32514886
Drug: SWIG (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SWIG (5 mg/kg intravenous)
Study: 32514886
Drug: 5-ALA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ALA (20 mg/kg oral)
Study: 32514886
Drug: SWIG (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SWIG (2.5 mg/kg intravenous)
Study: 32515349
Drug: 'agonist-only' Activin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 'agonist-only' Activin A muteins that activate ACVR1B but cannot form the non-signaling complex (NSC) with ACVR1
Study: 32516377
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg, 3 courses)
Study: 32517405
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane (ESP) block with 20 mL of 0.5% plain bupivacaine
Study: 32517690
Drug: Glucocorticoids and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids and hormone replacement
Study: 32518208
Drug: hs-cTnT >50
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT >50 ng/L
Study: 32518208
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hs-cTnT >50 ng/L and a second independent predictor
Study: 32518419
Drug: Ruxolitinib (Rux)
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib (Rux) - Janus Kinase 1/2 inhibitor, administered with efficacy/toxicity guided step up dosing up to 14 days
Study: 32518518
Drug: Nurse-led, person-centred,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led, person-centred, health-promoting follow-up programme (includes two telephone calls and three visits to a vascular nurse in the first year after surgical treatment)
Study: 32518518
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (visit to a vascular surgeon 4-8 weeks after surgery and a visit to the outpatient clinic 1 year after surgical treatment)
Study: 32518597
Drug: Steroidal aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroidal aromatase inhibitors
Study: 32518597
Drug: Nonsteroidal aromatase
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal aromatase inhibitors
Study: 32518833
Drug: Regular cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular cohort (three initial monthly IVT-AFL injections and ≥6 injections)
Study: 32518833
Drug: Irregular cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irregular cohort with three initial monthly injections
Study: 32518833
Drug: Irregular cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irregular cohort without three initial monthly injections
Study: 32518833
Drug: Regular cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular cohort vs irregular cohort without three initial monthly injections
Study: 32518833
Drug: Irregular cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irregular cohort with three initial monthly injections vs irregular cohort without three initial monthly injections
Study: 32518861
Drug: Tolvaptan modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan modified-release (MR) 120 mg
Study: 32518861
Drug: Tolvaptan immediate-release
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan immediate-release (IR) 90+30 mg
Study: 32518861
Drug: Tolvaptan MR
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan MR (various doses 20 to 120 mg)
Study: 32518862
Drug: Tolvaptan MR
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan MR 50 mg once daily
Study: 32518862
Drug: Tolvaptan MR
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan MR 80 mg once daily
Study: 32518862
Drug: Tolvaptan IR
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan IR 60/30 mg daily split dose
Study: 32518891
Drug: Seasonal trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal trivalent split, inactivated influenza vaccine (TIV) 0.5 ml (15 µg of hemagglutinin per strain)
Study: 32521310
Drug: Camidanlumab tesirine
Normalized name: Camidanlumab tesirine
DrugBank: Camidanlumab tesirine (DB16411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camidanlumab tesirine at 3-92 μg/kg Q3W (n = 26) or 30 or 37.5 μg/kg QW (n = 9)
Study: 32521607
Drug: B cell
Normalized name: B cell antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: B cell targeted therapies
Study: 32522280
Drug: Iodine-to-creatinine ratio
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-to-creatinine ratio (I:Cr) at 25th percentile (59 μg/g)
Study: 32522280
Drug: Iodine-to-creatinine ratio
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-to-creatinine ratio (I:Cr) at 75th percentile (121 μg/g)
Study: 32522846
Drug: ACE2 activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE2 activity enhancement drugs
Study: 32522846
Drug: RAS blockers
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RAS blockers (ACE inhibitors and angiotensin II receptor blockers)
Study: 32523090
Drug: E7449 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7449 (600 mg, maximum-tolerated dose)
Study: 32523090
Drug: E7449 (50-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7449 (50-800 mg doses)
Study: 32523090
Drug: E7449 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7449 (800 mg)
Study: 32523090
Drug: E7449 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7449 (600 mg)
Study: 32523648
Drug: Metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin alone (Arm A)
Study: 32523648
Drug: Metformin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin with rapamycin (Arm B)
Study: 32523873
Drug: Blended cognitive
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended cognitive behavioral therapy (CBT) combining online intervention and in-person guidance.
Study: 32523873
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral therapy (iCBT).
Study: 32524053
Drug: Perampanel monotherapy
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel monotherapy at 4 mg/d during the 26-week Maintenance Period
Study: 32524053
Drug: Perampanel monotherapy
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel monotherapy at 4 or 8 mg/d during the 26-week Maintenance Period
Study: 32524053
Drug: Perampanel monotherapy
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel monotherapy at 4 mg/d during Maintenance
Study: 32524053
Drug: Perampanel monotherapy
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel monotherapy at 4 or 8 mg/d during Maintenance
Study: 32524319
Drug: ABBV-176 (2.7-109.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-176 (2.7-109.35 μg/kg)
Study: 32525018
Drug: Days on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days on renal replacement therapy
Study: 32526533
Drug: Warfarin or
Normalized name: warfarin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin or DOACs
Study: 32527643
Drug: Autologous anti-EGFR
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous anti-EGFR chimeric antigen receptor-modified T (CAR T-EGFR) cells, median dose of CAR T cells: 3.48 × 10^6 cells, administered in one to three cycles within 6 months.
Study: 32528286
Drug: Olanzapine treatment
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine treatment for 12 weeks
Study: 32528389
Drug: Dog-assisted therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dog-assisted therapy (DAT)
Study: 32528722
Drug: Optimized APD
Normalized name: APD-209
DrugBank: APD-209 (DB18759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized APD (7 × 2 L 2.27% + 5 × 2 L 0.1% over 8 h)
Study: 32528722
Drug: Standard APD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard APD (6 × 2 L 1.36% over 9 h)
Study: 32529175
Drug: Doxycycline for
Normalized name: Doxycycline for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline for 1 year along with chemotherapy
Study: 32529495
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg loading dose at weeks 0, 2, and 4, followed by 200 mg every 2 weeks up to week 48
Study: 32530764
Drug: Ivosidenib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivosidenib (500 mg once per day)
Study: 32531990
Drug: Conventional disease-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional disease-modifying anti-rheumatic drug (cDMARD) therapy
Study: 32532097
Drug: H7N9 live
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H7N9 live attenuated influenza vaccine (LAIV) administered intranasally, two doses.
Study: 32532097
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intranasally, two doses.
Study: 32532225
Drug: Two-way messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-way messaging therapy
Study: 32532234
Drug: RTS,S/AS01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 vaccine (four-dose series: primary three doses followed by a fourth dose approximately 18 months later)
Study: 32532234
Drug: RTS,S/AS01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 vaccine (four-dose series)
Study: 32536573
Drug: Magnetic resonance-guided
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic resonance-guided radiation therapy (MRgRT)
Study: 32536979
Drug: YYB101 (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: YYB101 (0.3, 1, 3, 5, 10, 20, 30 mg/kg) administered intravenously once every 4 weeks for 1 month, then once every 2 weeks until disease progression or intolerable toxicity
Study: 32536979
Drug: YYB101 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: YYB101 (20 mg/kg)
Study: 32536984
Drug: Stepwise tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stepwise tapering of rhTNFR:Fc
Study: 32536984
Drug: Delayed tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed tapering of rhTNFR:Fc
Study: 32536984
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of rhTNFR:Fc
Study: 32536984
Drug: rhTNFR:Fc 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTNFR:Fc 25 mg monthly
Study: 32538690
Drug: Pazopanib (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (dosage and duration not available)
Study: 32539744
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections of 0.5 mg ranibizumab under '1 + PRN' regimen
Study: 32539794
Drug: 2.7 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.7 g/day of DHA
Study: 32539794
Drug: 2.7 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.7 g/day of EPA
Study: 32539794
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day of corn oil (control)
Study: 32540647
Drug: Continuous motion
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous motion monitoring based localization (Calypso) with initial localization, CBCT, pre-treatment motion correction by kV-imaging, and gating during irradiation (strategy A)
Study: 32540647
Drug: Non-gated treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-gated treatments (strategy B)
Study: 32540838
Drug: Tele-Exercise and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele-Exercise and Multiple Sclerosis (TEAMS) intervention, 12-week complementary and alternative medicine (CAM) intervention with 20 sessions of synchronous training sessions of dual tasking, yoga, and Pilates exercises.
Study: 32540858
Drug: Tislelizumab 0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 0.5, 2, 5 or 10 mg/kg every 2 weeks; 2 or 5 mg/kg every 2 or 3 weeks; or 200 mg every 3 weeks (Phase IA)